tacrolimus

Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.

Cross Reference

Introduction

To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with tacrolimus?

tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with tacrolimus

MeSH term MeSH ID Detail
Hypersensitivity D006967 22 associated lipids
Osteosarcoma D012516 50 associated lipids
Acne Vulgaris D000152 35 associated lipids
Urination Disorders D014555 9 associated lipids
Arterial Occlusive Diseases D001157 12 associated lipids
Anemia, Hemolytic D000743 4 associated lipids
Leukemia, Erythroblastic, Acute D004915 41 associated lipids
Vision Disorders D014786 10 associated lipids
Multiple Myeloma D009101 13 associated lipids
Osteochondrodysplasias D010009 3 associated lipids
Melanoma D008545 69 associated lipids
Hematologic Diseases D006402 3 associated lipids
Muscular Dystrophies D009136 10 associated lipids
Osteoporosis D010024 12 associated lipids
Anemia, Aplastic D000741 6 associated lipids
Kidney Diseases D007674 29 associated lipids
Hematuria D006417 13 associated lipids
Weight Gain D015430 101 associated lipids
Brain Diseases D001927 27 associated lipids
Cardiovascular Diseases D002318 24 associated lipids
Per page 10 20 50 100 | Total 613

PubChem Associated disorders and diseases

What pathways are associated with tacrolimus

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with tacrolimus?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with tacrolimus?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with tacrolimus?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with tacrolimus?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with tacrolimus?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with tacrolimus

Download all related citations
Per page 10 20 50 100 | Total 15051
Authors Title Published Journal PubMed Link
Sugimoto K et al. Assessment of Long-Term Efficacy and Safety of Adalimumab in Patients with Ulcerative Colitis: Results from a 6-Year Real-World Clinical Practice. 2019 Dig Dis pmid:30205400
Gaynor JJ and Ciancio G The Importance of Using Serially Measured Tacrolimus Clearance Values, Especially During the Early Posttransplantation Period. 2018 Transplantation pmid:29271869
Nakamura K et al. Prevention of chronic renal allograft rejection by AS2553627, a novel JAK inhibitor, in a rat transplantation model. 2018 Transpl. Immunol. pmid:28988984
Felipe C et al. Adequacy of Initial Everolimus Dose, With and Without Calcineurin Inhibitors, in Kidney Transplant Recipients. 2018 Ther Drug Monit pmid:29271815
Sablik KA et al. Tacrolimus intra-patient variability is not associated with chronic active antibody mediated rejection. 2018 PLoS ONE pmid:29746495
Thishya K et al. Artificial neural network model for predicting the bioavailability of tacrolimus in patients with renal transplantation. 2018 PLoS ONE pmid:29621269
Goto T et al. Prospective observational study on the first 51 cases of peripheral blood stem cell transplantation from unrelated donors in Japan. 2018 Int. J. Hematol. pmid:29027623
Liu J et al. Donor and recipient P450 gene polymorphisms influence individual pharmacological effects of tacrolimus in Chinese liver transplantation patients. 2018 Int. Immunopharmacol. pmid:29454235
Yoon CH et al. Topical Tacrolimus 0.03% for Maintenance Therapy in Steroid-Dependent, Recurrent Phlyctenular Keratoconjunctivitis. 2018 Cornea pmid:29309358
Buchholz BM et al. Role of colectomy in preventing recurrent primary sclerosing cholangitis in liver transplant recipients. 2018 World J. Gastroenterol. pmid:30065563